Prof. Mai Haiqiang, was born in January 1973. He is a professor, chief physician, director of Department of Nasopharyngeal Carcinoma, doctoral advisor, a member of the Editorial Board of Chinese Journal of Cancer, a member of Committee of Nasopharyngeal Cancer under Chinese Anti-Cancer Association, an evaluation expert of National Natural Science Foundation of China and a special reviewer for BMC Cancer and Tumor Biology. He specializes in nasopharyngeal carcinoma early diagnosis, individualized combination therapy, curative effect prediction and prognosis studies.

Nasopharyngeal carcinoma early diagnosis, individualized combination therapy, curative effect prediction and prognosis study

09/1991-06/1998  Seven-Year Master Program of Clinical Medicine, former Sun Yat-sen University of Medical Sciences

09/2002-06/2005  MD at Sun Yat-sen University

Publications as the first author or corresponding author (*, a mark of corresponding author):

1. Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ*. Emerging treatment options for nasopharyngeal carcinoma. Drug Des Devel Ther. 2013;7:37-52.

2. Liu H, Chen QY, Guo L, Tang LQ, Mo HY, Zhong ZL, Huang PY, Luo DH, Sun R, Guo X, Cao KJ, Hong MH, Mai HQ*.Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis. Radiat Oncol. 2013;8(1):70.

3. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, Wen BX, Wu YS, Mai HQ*, Hong MH. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial. Eur J Cancer. 2013 Feb 21. [Epub ahead of print]

4. Mo HY, Sun R, Sun J, Zhang Q, Huang WJ, Li YX, Yang J, Mai HQ*. Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma. Radiat Oncol. 2012;7(1):149.

5. Mo HY, Luo DH, Qiu HZ, Liu H, Chen QY, Tang LQ, Zhong ZL, Huang PY, Zhao ZJ, Zhang CQ, Zhang Y, Mai HQ*. Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma. Clin Oncol. 2013 Jan 2. [Epub ahead of print]

6. Huang PY, Sun ZY, Xie CM, Chen QY, Wen YF, Li J, Qiu HZ, Liu H, Zhong ZL, Mai HQ*, Mo HY. Prognostic significance of the various classifications for parapharyngeal space involvement in nasopharyngeal carcinoma. Acta Otolaryngol. 2012;132(11):1197-1207.

7. Li SX, Chen QY, Zhang YJ, Liu ZM, Xiong HL, Guo ZY, Mai HQ*, Liu SH. Detection of nasopharyngeal cancer using confocal Raman spectroscopy and genetic algorithm technique. J Biomed Opt. 2012;17(12):125003.

8. Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ*, Hong MH. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48(10):1038-1044.

9. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ*. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761-1770.

10. Wen YF, Qi B, Liu H, Mo HY, Chen QY, Li J, Huang PY, Ye YF, Zhang Y, Deng MQ, Guo X, Hong MH, Cao KJ, Mai HQ*.Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma. Clin Cancer Res. 2011;17(8):2451-2458.

11. Mai HQ, Mo HY, Deng JF, Deng MQ, Mai WY, Huang XM, Guo X, Hong MH. Endoscopic microwave coagulation therapy for early recurrent T1 nasopharyngeal carcinoma. Eur J Cancer. 2009;45(7):1107-1110.

12. Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY, Hong MH. Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Sci. 2006;97(12):1388-1395.

13. Mai HQ, Zeng ZY, Zhang CQ, Feng KT, Guo X, Mo HY, Deng MQ, Min HQ, Hong MH. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer. 2006;106(7):1548-1553.

14. Mai HQ, May WS, Gao F, Jin Z, Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem. 2003;278(3):1886-1891.

15. Mai HQ, Xu LH, Liu H, Mo HY, Huang PY, Tang LQ, Chen QY. Endothelin-1 promotes 6-10B nasopharyngeal carcinoma cell migration by inducing the expression of chemokine receptor CXCR4. Journal of Sun Yat-sen University (Medical Sciences). 2011;32(5):616-622.

16. Qi B, Guo X, Wen YF, Mo HY, Chen QY, Liu H, Li J, Ye YF, Mai HQ*. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in locoregionally advanced nasopharyngeal carcinoma. Chinese Journal of Cancer Prevention and Treatment. 2010;17(10): 755-758.

17. Chen QY, Zhang CQ, Mo HY, Deng MQ, Cao SM, Hong MH, Guo X, Mai HQ*. Dynamic changes of serum VEGF of nasopharyngeal carcinoma patients during radiotherapy. Chinese Journal of Cancer Prevention and Treatment. 2009;16(18):1424-1426.

18. Huang WJ, Mo HY, Deng MQ, Mai HQ*, Qi B, Li J, Hong MH, Guo X. Relationship between cranial nerve involvement in nasopharyngeal carcinoma and the prognosis. Journal of Clinical Otorhinolaryngology Head and Neck Surgery. 2009;23(21):964-967.

19. Qi B, Guo X, Wen YF, Mo HY, Chen QY, Liu H, Li J, Ye YF, Mai HQ*. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in locoregionally advanced nasopharyngeal carcinoma. Chinese Journal of Cancer Prevention and Treatment. 2010;17(10):755-758.

20. Chen QY, Zhang CQ, Mo HY, Deng MQ, Cao SM, Hong MH, Guo X, Mai HQ*. Dynamic changes of serum VEGF of nasopharyngeal carcinoma patients during radiotherapy. Chinese Journal of Cancer Prevention and Treatment. 2009;16(18):1424-1427.

21. Huang WJ, Mo HY, Deng MQ, Mai HQ*, Qi B, Li J, Hong MH, Guo X. Relationship between cranial nerve involvement in nasopharyngeal carcinoma and the prognosis. Journal of Clinical Otorhinolaryngology Head and Neck Surgery. 2009;23(21):964-967.

22. Deng MQ, Mai HQ*, Mai WY, Mo HY, Huang XM, Guo X, Hong MH. Endoscopic microwave coagulation therapy for locally recurrent nasopharyngeal carcinoma. Chinese Journal of Cancer. 2008; 27(7):734-737.

23. Zhao ZJ, Mo HY, Zhang CQ, Qi B, Li J, Hong MH, Mai HQ*. Correlation of pretreatment serum level of endostatin to posttreatment distant metastasis in patients with advanced nasopharyngeal carcinoma. Chinese Journal of Cancer. 2007;26(11):1243-1247.

24. Mai HQ, Zeng ZY, Zhang HZ, Hou JH, Mo HY, Guo X,Min HQ, Hong MH. Correlation of endothelin a receptor expression to prognosis of nasopharyngeal carcinoma. Chinese Journal of Cancer. 2005;24(5):611-615.

25. Mai HQ, Mo HY, Hong MH, Guo X, Deng MQ, Zhang F, Min HQ. Impact of pre-radiotherapy hemoglobin level on local control of nasopharyngeal carcinoma. Chinese Journal of Cancer. 2005;24(6):89-92.

26. Ma J, Mai HQ*, Hong MH, Mo HY, Cui NJ, Lu TX, Min HQ. Clinical evaluation of 1997 UICC staging system for nasopharyngeal carcinoma. Chinese Journal of Cancer. 2001;20(3):301-304.

27. Mai HQ, Huang XM, Zhang F, Deng MQ, Guo X, Min HQ. Clinical analysis on osteoradionecrosis of skull base in patients with nasopharyngeal carcinoma after radiotherapy. Chinese Journal of Cancer. 2001;20(1):69-71.

28. Mai HQ, Ma J, Zhang JM, Huang TB, Mo YX. Effect of computed tomography on N-staging for nasopharyngeal carcinoma. Chinese Journal of Cancer. 2000;19(9):907-910.

29. Ma J, Mai HQ*, Mo HY, Lu TX, Cui NJ, Hong MH. Patterns of treatment failure after primary radiotherapy in patients with nasopharyngeal carcinoma. Chinese Journal of Cancer. 2000;19(11):1016-1018.

Edited Works:

1. Mai HQ. ‘Endoscopy and Differential Diagnosis’, in Min HQ, Hong MH, Guo X, Nasopharyngeal Carcinoma. Beijing: China Medical Science Press. 2003;Edition 1:101-114.

2. Mai HQ. ‘Prognosis and Prognostic Factors’, in Min HQ, Hong MH, Guo X, Nasopharyngeal Carcinoma. Beijing: China Medical Science Press. 2003;Edition 1:379-397.

3. Mai HQ (Editorial Board Member). ‘Nasopharyngeal Carcinoma’, in International Comparative Study on the Scientific and Technological Innovation Ability of Chinese Modern Medicine, organized by China National Center for Biotechnology Development. Beijing: China Medical Science Press. 2009.

4. Mai HQ, Huang WL (Eds). Biopharmaceutical “Miracles” -- The Birth and Development of Gene Medicine. Guangzhou: Guangdong Science and Technology Press. 2011.

5. Mai HQ (Editorial Board Member). ‘Nasopharyngeal Carcinoma’, in A Course in Advanced Clinical Oncology. Beijing: People’s Military Medical Press. 2011.

6. Mai HQ (Subeditor). Diagnosis and Treatment of Nasopharyngeal Carcinoma. World Publishing Corporation. 2012.

Honors and Awards:

1. 2012 The 3rd Guangdong Science and Technology Innovation Excellent Academic Papers First Prize

2. 2012 The Seventh Batch of Provincial Talents for Guangdong “Ten-Hundred-Thousand” Project

3. 2011 Ministry of Education Program for New Century Excellent Talents in University

4. 2009 Dr. Cheng Yu Tung Fellowships awarded by the Li Ka Shing Faculty of Medicine at the University of Hong Kong

5. 2009 The second National Prize for Progress in Science and Technology with “Research and Application of Comprehensive Treatment of Nasopharyngeal Carcinoma Based on Modern Imaging Technology” (the fourth author)

6. 2008 The 5th “Ten Outstanding Young Persons of Yunfu City”

7. 2008 The first Guangdong Provincial Science and Technology Award with “Research of Comprehensive Treatment of Nasopharyngeal Carcinoma Based on Modern Imaging Technology” (the fourth author)

8. 2008 The second Prize for Progress in Science and Technology of Ministry of Education with “Research of Comprehensive Treatment of Nasopharyngeal Carcinoma Based on Imaging ” (the fourth author)

9. 2007 The first Science and Technology Award of Chinese Medical Association with “Research of Comprehensive Treatment of Nasopharyngeal Carcinoma Based on Modern Imaging Technology” (the fourth author)

10. 2007 “Cancer Science Young Scientists Award” of Japanese Cancer Association

Updated by International Office, Sun Yat-sen University Cancer Center

2. Chinese Research Progress in Cancer -- Prevention and Treatment Work in Chinese Cancer High Occurrence Sites, Dong Zhiwei Chief Editor: Guo Xiang, Xiang Yanqun, Min Huaqing. Research of screening and early diagnosis and treatment of nasopharynx carcinoma, Peking University Medical Press, 2007; pp: 401-417

Updated by International Office, Sun Yat-sen University Cancer Center

Prof. Guo Xiang was born in December 1963. In June 1988, he graduated from Department of Clinical Medicine of former Sun Yat-sen University of Medical Sciences and received the Doctoral Degree in Clinical Oncology. From September 1997 to January 1998, he further studied in Radiation Oncology of Shanghai Medical College of Fudan University; from June 2000 to June 2002, he received post-doctoral training in Van Andel Research Institute (VARI) in America, primarily engaging himself in the research on the application of gene chips in cancer; from 2002 in April to June 2002, he served as a visiting scholar and studied in William Beaumont Hospital’s Cancer Institute in the United States. Currently, he works as the Chief Physician, doctoral advisor and Associate Chief for Department of Nasopharyngeal Carcinoma, member and secretary of Chinese Society of Nasopharyngeal Carcinoma, Chinese Anti-cancer Association, editorial board member of Chinese Journal of Cancer and expert reviewer to Chinese Journal of Clinical Oncology.
 
After graduating from the undergraduate program, he worked in school and entered the Head and Neck at the Sun Yat-sen University Cancer Center (SYSUCC), engaging himself in medical treatment, teaching and scientific research. He masters solid theoretical basis for oncology and surgical basic skills and accumulates abundant experience in clinical practice. Since 1995, he has specialized in nasopharynx carcinoma’s clinical diagnosis and treatment, scientific research and teaching. Type of Work: clinical diagnosis, combination therapy, and research on the biological features of nasopharynx carcinoma; surgical treatment of recurrent nasopharynx carcinoma (including minimally invasive surgery of recurrent or residual nasopharyngeal carcinoma, surgical treatment of recurrent or residual cervical lymph nodes and surgical treatment of complications caused by radiotherapy); research on the biological features of nasopharynx carcinoma. He served as editor-in-chief in compilation of one monograph, co-wrote five monographs and published over 20 papers.

1. Diagnosis and combination therapy of nasopharynx carcinoma
2. Rescue surgical treatment of nasopharynx carcinoma
3. Surgical treatment of complications and sequelae after radiotherapy of nasopharynx carcinoma
4. Study on the biological characteristics of nasopharynx carcinoma

09/1982 – 06/1988: Department of Clinical Medicine of former Sun Yat-sen University of Medical Sciences

09/1994 – 06/1997: Studied to obtain the Doctoral Degree in Clinical Oncology in former Sun Yat-sen University of Medical Sciences and received the Doctoral Degree

09/1997 - 01/1998: Further studied in the Radiation Oncology at the Shanghai Medical College of Fudan University

06/2000 – 06/2002: Studied to obtain the Postdoctoral Degree from Van Andel Research Institute (USA)

04/2002 – 06/2002: Studied as a visiting scholar at the William Beaumont Hospital’s Cancer Institute in the United States

Main Publications (* Corresponding author):
1. Wang FL, Guo X*, Yuan ZT, Cao SM, Rao HL, Hong JH, Shao Q, Li NW, Hong MH. Expression and clinical significance of Wnt-1 andβ-catenin in nasopharyngeal carcinoma. Chinese Journal of Cancer, 2009; 28 (1): 91-95.

2. Mo HY, Deng MQ, Mai HQ, Qi B, Li NW, Guo X, Hong MH. The influences and treatment of deafness in nasopharyngeal carcinoma patients after radiotherapy. Modern Oncology, 17 (10): 1856-58. 

3. Hua YJ, Chen MY, Qian CN, Hong MH, Zhao C, Guo L, Guo X, Cao KJ. Postradiation nasopharyngeal necrosis in the patients with nasopharyngeal carcinoma. Head Neck. 2009 Jun;31(6):807-12.

4. Mai HQ, Mo HY, Deng JF, Deng MQ, Mai WY, Huang XM, Guo X, Hong MH. Endoscopic microwave coagulation therapy for early recurrent T1 nasopharyngeal carcinoma. Eur J Cancer. 2009 May;45(7):1107-10.

5. Chen MY, Wen WP, Guo X, Yang AK, Qian CN, Hua YJ, Wan XB, Guo ZM, Li TY, Hong MH.  Endoscopic nasopharyngectomy for locally recurrent nasopharyngeal carcinoma. Laryngoscope. 2009 Mar;119(3):516-22. 

6. Liu TR, Yang AK, Guo X, Li QL, Song M, He JH, Wang YH, Guo ZM, Zhang Q, Chen WQ, Chen FJ. Adenoid cystic carcinoma of the nasopharynx: 27-year experience. Laryngoscope. 2008 Nov;118(11):1981-8.

7. Qi Z, Guo X *, Li NW, Xiang YQ, Cao SM, Hong MH. Clinical Characteristics and Prognosis of Aged Nasopharyngeal Carcinoma Patients: A Report of 313 Cases. Chinese Journal of Cancer, 2008; 27 (3): 289-294.

8. Yuan TZ, Guo X *, Zheng L, Cao SM, Li NW, Xiang YQ. Occurrence and Influencing Factors of Paranasal Sinusitis in Nasopharyngeal Carcinoma Patients after Radiotherapy. Chinese Journal of Cancer, 2008; 27 (8): 866-869.

9. Yuan TZ, Li XX, Cao Y, Qian CN, Zeng MS, Guo X *. Correlation of Epidermal Growth Factor Receptor Activation to Metastasis-free Survival of Nasopharyngeal Carcinoma Patients. Chinese Journal of Cancer, 2008; 27 (5): 449-454.

10. Yuan TZ, Li NW, Cao SM, Qi Z, Guo X *. Peripheral nerve sheath tumors at the epithelioid cell type of nasopharyngeal skull base: A report of one case and literature review. Chin J Cancer Prev Treat, 2008 April; 15 (8):639-640.

11. Mr TQ, Mai HQ, Mai WY, Mo HY, Huang XM, Guo X, Hong MH. Endoscopic Microwave Coagulation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2008; 27 (7): 734-737.

12. Cao SM, Guo X *, Chen FuJ, Yang AK, Chen WK, Li NW. Serum Diagnosis of Head and Neck Squamous Cell Carcinoma Using Surface-enhanced Desorption Ionization Mass Spectrometry and Artificial Neural Network Analyses. Chinese Journal of Cancer, 2007; 26 (7): 767-770.

13. Chen MY, Guo X, Wen WP, Hua YJ, Guo L, Li NW, Chen QY, Sun R, Hong MH. Salvage Surgical Operation via Endoscopic Transnasal Approach for Local Persistent or Recurrent Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2007; 26 (7): 673-678.

14. Mo HY, Mai HQ, Li NW, Li J, Huang WJ, Guo X, Hong MH. Study of secretory otitis media after radiotherapy in nasopharyngeal carcinoma and inquisition of prevention and treatment. Chin J Cancer Prev Treat, 2007 July; 14 (13) 1005-1007.

15. Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY, Hong MH. Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.Cancer Sci. 2006 Dec; 97(12):1388-95. Epub 2006 Oct 9.

16. Mai HQ, Zeng ZY, Zhang CQ, Feng KT, Guo X, Mo HY, Deng MQ, Min HQ, Hong MH.  Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer. 2006 Apr 1; 106(7):1548-53.

17. Cao SM, Guo X *, Li NW, Xiang YQ, Hong MH, Min HQ. Clinical analysis of 1142 Hospitalized Cantonese Patients with Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2006 Feb; 25 (2):204-208.

18. Xiang YQ, Yao HR, Wang SS, Hong MH, He JH, Cao SM, Min HQ, Song EW, Guo X*. Prognostic Value of Survivin and Livin in Nasopharyngeal Carcinoma. Laryngoscope, 2006 Jan; 116(1):126-130.

19. Guo X*, Cao SM, Yu JK, Hong MH, Zhang CQ, Li NW, Xiang YQ, Qian CN, Hu X, Min HQ, Zeng YX. Distinct serumal proteomic patterns between ascending and descending types of loco-regionally advanced nasopharyngeal carcinoma assessed by surface enhanced laser desorption ionization and artificial neural network analyses. Chin Med J (Engl), 2005 Nov; 118(22):1912-1917.

20. Xiang YQ, Yao RH, Guo X *, Hong MH, Cao SM, Min HQ. Expression of survival in nasopharyngeal carcinoma and its prognostic significance. Chin J Cancer Prev Treat, 2006 Jan; 13 (2):120-123.

21. Cao SM, Guo X, Li NW, Hong MH, Min HQ. The Family Clustering Study of Nasopharyngeal Carcinoma Patients in Guangdong. Cancer Research on Prevention and Treatment, 2006 Apr; 33 (4):283-285.

22. Sun ZY, Mai HQ, Xie CM, Zhao ZJ, Qi B, Hong MH, Guo X, Mo HY.  Prognostic influence of parapharyngeal space involvement in nasopharyngeal carcinoma. Chin J Cancer Prev Treat, 2006; 13 (10): 756-759.

23. Guo L, Lin HX, Qiu F, Luo HD, Sun R, Guo X, Hong MH. Concurrent Chemoradiotherapy Using Oral Capecitabine and Carboplatin in the Treatment of Elderly Patients with Advanced Nasopharyngeal Carcinoma. Cancer Research on Prevention and Treatment, 2006; 33 (5): 368-370.

24. Xiang YQ, Zhao HR, Guo X *, Hong MH, Cao SM, Min HQ. Apoptosis of Nasopharyngeal Carcinoma SUNE-1 Cell Lines Induced by inhibitors of Topoismerase II. Chinese Journal of Clinical Oncology, 2005 Dec; 32 (24): 406-1409.

25. Xiang YQ, Zhao HR, Guo X *, Hong MH, Cao SM, Min HQ. Apoptosis of Nasopharyngeal Carcinoma CNE-2 Cell Lines Induced by Topoismerase II, ADM and THP. Journal of Sun Yat-sen University (Medical Sciences), 2005; 26 (3S): 70-72. 

26. Akervall J, Guo X (Co-first author), Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clinical Cancer Research, 2004 Dec; 10(24): 8204-8013. 

27. Guo X, Cao SM, Hong MH, Zhang CQ, Han AJ, Xiang YQ, Hou JH, Min HQ. Clinical Value of Vascular Endothelial Growth Factor Detection in Forecasting Distant Metastasis Risk of Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2004; 23 (10): 1171-75.

28. Xiang YQ, Min HQ, Hong MH, Cao SM, He JH, Hou JH, Guo X*. Expression of Topoisomerase IIα in Nasopharyngeal Carcinoma and Its Clinical Significance. Chinese Journal of Cancer, 2004; 23 (3): 322-325. 

29. Guo X, Lui WO, Qian CN, Chen JD, Gray SG, Rhodes D, Haab B, Stanbridge E, Wang H, Hong MH, Min HQ, Larsson C, Teh BT.  Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses.  Int J Oncol., 2002 Dec; 21(6):1197-1204.

30. Hong MH, Min QH, Guo X *, Ma J, Mai HQ, Zhang WT, Zhang F, Zhang JM. To prove the rationality of ’92 staging with results of nasopharyngeal carcinoma treated by stratified multitherapies. Chinese Journal of Cancer, 2000; 19 (5): 460-2.

31. Guo X *, Min HQ, Huang XM, Zhang JM, Chen FJ. The maxillary swing approach for resection of nasopharyngeal carcinoma. Chinese Journal of Cancer, 1999; 18 (2): 187-189.

32. Guo X*, Min HQ, Zeng MS, Qian CN, Huang XM, Shao JY, Hou JH. nm23-H1 expression in nasopharyngeal carcinoma: correlation with clinical outcome.  Int J Cancer. 1998 Dec; 18; 79 (6):596-600.

33. Guo X*, Min Huaqing, Shao Jianyong, Hou Jinhui. Expression of Nm23-H1 Gene Product in Nasophartngeal Carcinoma and Its Clinical Significance. Chinese Journal of Cancer Research, 1998; 10(1): 49-53.

34. Guo X *, Min HQ, Huang XM, Zhang JM, Chen FJ, Qian CN. Exploration of new approach to salvage surgical operation of nasopharyngeal carcinoma -- the inverted maxillary approach for resection. Chinese Journal of Cancer, 1998; 17 (4): 271-273. 

35. Guo X *, Min HQ, Zhao JY, Hou JH. Expression and clinical significance of gene products of Nm23-H in the human nasopharyngeal carcinoma. Chinese Journal of Cancer, 1997; 16 (2): 119-122. 

36. Guo X *, Min QH. Salvage surgical operation of nasopharyngeal carcinoma (Review). China Cancer, 1997; 6 (7): 18-20. 

37. Guo X *, Min HQ, Zeng ZY, Chen FJ. Esthesioneuroblastoma (clinical analysis of 23 cases). Chinese Journal of Trauma and Distablity Medicine, 1996; 4 (3): 30-31. 

38. Xial LP, Zeng ZY, Chen ZH, Guo ZM, Guo X, Zhang Q. Surgery for the recurrent and persistent lymph node of nasopharyngeal carcinoma after radiotherapy. Chin J Otorhinolaryngol Head Neck Surg, 2005; 140 (2): 95-99. 

39. Mai, HQ, Mo HY, Hong MH, Guo X, Deng MQ, Zhang F, Min HQ. Impact of Pre-radiotherapy Hemoglobin Level on Local Control of Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2005; 24 (6): 727-730.

40. Lindvall C, Furge K, Bjorkholm M, Guo X, Haab B, Blennow E, Nordenskjold M, Teh BT. Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica, 2004 Sep; 89(9):1072-81.

41. Gray SG, Qian CN, Furge K, Guo X, Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol, 2004 Apr; 24(4):773-95.

42. Fuh-Mei Duh, Matthew Fivash, Michele Moody, Maria Li Lung, Xiang Guo, Eric Stanbridge, Michael Dean, Michael Voevoda, Li-Fu Hu, Vladimir Kashuba, Eugene R. Zabarovsky, Chao-Nan Qian, Sharad Godbole, Bin Tean Teh and Michael I. Lerman. Characterization of a new SNP c767A/T (Arg222Trp) in the candidate TSG FUS2 on human chromosome 3p21.3: prevalence in Asian populations and analysis of association with nasopharyngeal cancer. Molecular and Cellular Probes, 2004; 18(1):39-44.

43. Cao SM, Min HQ, Gao JS, Hong MH, Xiao XB, Zhang CQ, Liu XD, Zhang AL, Guo X. Significance of Cell-free Epstein-Barr Virus DNA in Monitoring Prognosis of Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2003; 22 (3): 302-6.

44. Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH, Vande Woude GF, Resau JH, Teh BT. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.  Cancer Res., 2002 Jan 15; 62(2):589-96.

45. Xiang YQ, Guo X, Hong MH. Progress in studying molecule markers of nasopharyngeal carcinoma. Journal of Practical Oncology, 2004; 19 (4): 273-275.

46. Tao JP, Li MZ, Wang HM, Guo X, Hong MH. Study on the Tumorigenicity of Nasopharyngeal Carcinoma Cells Transfected with Haman IL-18 cDNA in Hu-PBL-SCID Mice. Current Immunology (Shanghai Journal of Immunology), 2002; 22 (6): 408-410.

47. Gray SG, Guo X, Kedra D, Teh BT, Guo X, Min HQ.  Correspondence re: P. P. Claudio et al., Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res., 60: 8-12, 2000. Cancer Res. 2001 Aug 1; 61(15):5950-5953.

48. Mai HQ, Huang XM, Zhang F, Deng MQ, Guo X, Min HQ. Clinical Analysis on Osteoradionecrosis of Skull Base in Patients with Nasopharyngeal Carcinoma after Radiotherapy. China Journal of Cancer, 2001; 20 (1): 69-71.

49. Qian CN, Zhang CQ, Guo X, Hong MH, Cao SM, Mai WY, Min HQ, Zeng YX.  Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma.  Cancer, 2000 Jan 15; 88(2): 255-261.

50. Min HQ, Guo X. Retrospect and prospect of study on nasopharyngeal carcinoma. Foreign Medical Sciences (Cancer Section), 2000; 27 (1): 11-14.

51. Yang AK, Guo X. Clinical analysis of mucosal malignant melanoma of head and neck. Cancer Research on Prevention and Treatment, 2000; 27 (4): 309-310. 

52. Min HQ, Hong MH, Guo X, Qian XN. Progress in study of nasopharyngeal carcinoma. China Cancer, 1999; 8 (12): 558-561.

53. Yang SC, Li SN, Liu F, Mai WY, Guo X. Changes in the Th1 cells in peripheral blood of patients with nasopharyngeal carcinoma and its relation to the course. Chinese Journal of Immunology, 1998; 14 (3): 220-223.

54. ang SC, Li SN, Liu F, Mai WY, Guo X. Transfection of B7-1 gene nasopharyngeal carcinoma cell lines and the cellular immune responses induced by transfection. Chinese Journal of Immunology, 1998; 14 (3): 172-175.

55. Guo X, Min HQ. Status of surgical operation in the treatment of nasopharyngeal carcinoma (Review). China Journal of Cancer, 1998; 17 (5): 394-396. 

56. Zeng MS, Guo X, Wang HM, Li MZ, Song LB, Yun JP, Guo HY. Expression of nm23-H1 mRNA and protein in nasopharyngeal carcinoma. Journal of Sun Yat-sen University, 1998; 19 (1): 7-10.

Major Monographs:
1. Hong MH, Guo X. Editor. Nasopharyngeal Carcinoma. China Medical Science Press, 2003. 

2. Guo X. Research on Screening and Early Diagnosis and Treatment for Nasopharyngeal Carcinoma. Edited by Dong ZW. Progress in China Research on Cancer (VIII). Peking University Medical Press, 2007; Pp401-417.

3. Guo X. Surgical Treatment for Nasopharyngeal Carcinoma. Edited by Zeng YX, Rong TH, Seminars on Nasopharyngeal Carcinoma. Zhengzhou University Press, 2006; Pp41-45. 

4. Guo X, Lu TX. Nasopharyngeal Carcinoma. Edited by Wan DS, Clinical Oncology (Second Edition). Science Press, 1999; pp: 217-229.

5. Guo X. Surgical Treatment. Edited by Hong MH and Guo X, Nasopharyngeal Carcinoma. China Medical Science Press, 2003; pp: 279-296. 

6. Guo X. Emergency Treatment. Edited by Hong MH and Guo X, Nasopharyngeal Carcinoma. China Medical Science Press, 2003; pp:346-351.   

7. Al-Sarraf, M., and Guo X. Head and Neck Cancers. In Cancer Chemotherapy and Biological Response Modifiers. Annual 21, G. Giaccone, R. Schilsky, and P. Sondel, 2003 Elsevier B.V., pp 430-443. 

8. Min HQ, Guo X. Nasopharyngeal Carcinoma. Edited by Li SL, New Head and Neck Oncology. Scientific and Technical Documentation Press, 2002; pp: 496-545. 

9. Guo X. Surgical Treatment of Nasopharyngeal Carcinoma. Edited by Min HQ, New Treatment Specifications of Common Cancers (Nasopharyngeal Carcinoma section). Peking Union Medical College Press,

10. Guo X. Surgical Treatment of Nasopharyngeal Carcinoma. Edited by Min HQ, Study on Nasopharyngeal Carcinoma. Guangdong Science & Technology Press, 1998: 265-280.

11. Guo X, Min HQ. Nasopharyngeal Carcinoma. Edited by Wang DS, Clinical Oncology. Science Press, 1998; pp: 122-32.
 

Research Projects:
1. Study on screening nasopharyngeal carcinoma metastasis-related genes with the technology of cDNA microarray (an international cooperation project of Guangdong Provincial Department of Science and Technology, undertaker)

2. Study on screening early nasopharyngeal carcinoma-specific serum protein with protein microarray (Guangdong Provincial Department of Science and Technology, undertaker) 

3. Study on screening nasopharyngeal carcinoma metastasis-related genes and predicting prognosis with the technology of cDNA microarray (Project 985, undertaker)

3. Role of IAP family proteins in prognosis of nasopharyngeal carcinoma (Hospital’s fund, undertaker).5. Application of protein microarray technology to screen marker nasopharyngeal carcinoma-specific serum protein markers (Hospital’s fund, undertaker).

1. Molecular biological characteristics of nasopharyngeal carcinoma in multi-stages of occurrence and development (Project 973, participant).

2. Research on screening nasopharyngeal carcinoma risk indicators of high-risk group(Health Department of Guangdong Province, participant).

 
Awards and Honors: 
1. Series research on prevention and treatment of nasopharyngeal carcinoma (the Second Class Award of State Science and Technology Advancement Award, 2000, No. 6, )

2. Research on ’92 staging and treatment of nasopharyngeal carcinoma (the First Class Award of Sci-Tech Advancement of Guangdong Province, 1999, No. 3)

3. Research on ’92 staging and treatment of nasopharyngeal carcinoma (the First Class Award of Health Department of Guangdong Province, 1999, No. 3)

4. Second-class Prize of “Mr. Deng Anticancer Science Award” (Sun Yat-sen University Cancer Center, 2006, Jan.)

5. Star of Technology, “Tianheng Cup” Award of Clinical Oncology Research Results (Sun Yat-sen University Cancer Center, 1999) 

6. Application of transnasal endoscopic surgery in the diagnosis and treatment of nasopharyngeal carcinoma, Third-class Prize in the Medical Achievement Award of Zhongshan School of Medicine (No. 041, Rank No. 2)

Updated by International Office, Sun Yat-sen University Cancer Center

Professor Chong Zhao is currently a Chief Physician, Professor and Master supervisor in the Department of Nasopharyngeal Carcinoma/Radiation Oncology of Sun Yat-sen University Cancer Center. He has been engaged in the area of radiation oncology for more than 30 years, and specializes in the diagnosis, radiotherapy and combined treatment of head and neck cancers, especially the intensity modulated radiotherapy (IMRT), chemoradiotherapy, targeted therapy, immunotherapy and nutritional therapy on nasopharyngeal carcinoma. Prof. Zhao is one of the top radiation oncologists in China, who lead in investigating the IMRT technique and optimizing target volumes delineation and dose modification for NPC from 2001. He has been in charge of or participated in more than 30 research projects supported by international, national or provincial funds. He is now leading several multicenter clinical trials in China. He has published more than 100 peer-reviewed papers in renowned international journals such as Annals of Oncology and International Journal of Radiation Oncology Biology Physics. Prof. Zhao is also the recipient of three National Science and Technology Progress Awards (2nd level) and one provincial and ministerial awards (1st level), including the Chinese Medical Science and Technology Award, among many more. Besides, he is the leader member of many academic committees.

Diagnosis, radiotherapy and combined treatment of head and neck cancers and has particular expertise in intensity modulated radiotherapy and chemo-radiotherapy concerning nasopharyngeal carcinoma.

Degrees, Board Certification
2019.06    Ph.D., Wuhan University
1986.06    M.B.B.S., Sun Yat-sen Medical University

Undergraduate Education
1980.09-1986.06   Sun Yat-sen Medical University

Post-graduate, Research, and Specialty Training
2016.09-2019.06    Wuhan University
2009.04-2009.10   Principles and practice of clinical research, The National Institutes of Health Clinical Center
2005.09-2007.09   Receive the Master's degree program, Sun Yat-sen University
1997.12-1998.01   Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

Seletected publications

1. Zhao C, Miao JJ, Shen GZ, Li JG, Shi M, Zhang N, Hu GQ, Chen XZ, Hu XF, Wu SX, Chen JX, Shao XF, Wang L, Han F, Mai HQ, Chua MLK, Xie C. Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody combined with Cisplatin and 5-Fluorouracil in Patients with Metastatic Nasopharyngeal Carcinoma after Radical Radiotherapy: A Multicentre, Open-label, Phase II Clinical Trial. Ann Oncol. 2019 Jan 23.

2. Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, Zhao YY, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Liang WH, Zhao C (Co-last Corresponding), Zhang L. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology,2013; 24: 2131–2136.

3. Miao JJ, Di MP, Chen BY, Wang L, Cao YQ, Xiao WW, Wong KH, Huang L, Zhu MY, Huang HG, Huang SM, Han F, Deng XW, Xiang YQ, Lv X, Xia WX, Tan SH, Wee JTS, Guo X, Chua MLK, Zhao C. A Prospective 10-year Observational Study of Reduction of Radiotherapy Clinical Target Volume and Dose in Early-stage Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2020 Apr 6. pii: S0360-3016(20)30959-7.

4. Zhao C, Miao JJ, Hua YJ, Wang L, Han F, Lu LX, Xiao WW, Wu HJ, Zhu MY, Huang SM, Lin CG, Deng XW, Xie CH. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):836-844.

5. Chen JZ, Le QT, Han F, Lu LX, Huang SM, Lin CG, Deng XW, Cui NJ, Zhao C. Results of a Phase II Study Examining the Effects of Omitting Elective Neck Irradiation to Nodal Levels IV and Vb in Patients with N0-1 Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics,2013; 85(4):929-934.

6. Di MP, Wang M, Miao JJ, Chen BY, Huang HG, Lin CY, Jian YT, Li Y, Ouyang Y, Chen XF, Wang L, Zhao C. CHAF1B induces radioresistance by promoting DNA damage repair in nasopharyngeal carcinoma. Biomed Pharmacother. 2020 Mar; 123:109748.

7. Miao JJ, Wang L, Zhu MY, Xiao WW, Wu HJ, Di MP, Huang YQ, Huang SM, Han F, Deng XW, Guo X, Zhao C. Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy. Oral Oncol. 2019 Mar; 90:126-133.

8. Peng YL, Chen L, Shen GZ, Li YN, Yao JJ, Xiao WW, Yang L, Zhou S, Li JX, Cheng WQ, Guan Y, Xia HQ, Liu S, Zhao C (Co-last Corresponding), Deng XW. Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma. Oral Oncol. 2018 Jul; 82:1-7.

9. Li Y, Tang LQ, Liu LT, Guo SS, Liang YJ, Sun XS, Tang QN, Bei JX, Tan J, Chen S, Ma J, Zhao C (3rd corresponding), Chen QY, Mai HQ. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Cancer Res Treat. 2018 Oct;50(4):1304-1315.

10. Shen GZ, Xiao WW, Han F, Fan W, Lin XP, Lu L, Zheng L, Yue N, Haffty B, Zhao C (Co-last Corresponding), Deng X. Advantage of PET/CT in Target Delineation of MRI-negative Cervical Lymph Nodes in Intensity-Modulated Radiation Therapy Planning for Nasopharyngeal Carcinoma. J Cancer. 2017 Nov 6;8(19):4117-4123.

Updated May 2020 by International Office, Sun Yat-sen University Cancer Center

Prof. Cao specializes in radiation therapy for nasopharyngeal carcinoma and lung cancer.

1. Diagnosis of and combination therapy for nasopharyngeal carcinoma (NPC)

2. Epidemiology of cancer

Monographs

1.Editor-in-chief of Registration and Statistics of Community Cancers

2.Editor of Nasopharyngeal Carcinoma, Oncological Symposium and other monographs
 
Papers (as lead author)

1. Chinese Medical Journal: Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission.

2. Chinese Journal of Oncology: Clinical Research on Prognostic Factors of Nasopharyngeal Carcinoma of Children

3. Chinese Journal of Oncology: Prognostic factors in nasopharyngeal carcinoma in childhood and adolescence

4. Chinese Journal of Oncology: Clinical Research on Prophylactic Cranial Irradiation in Small Cell Lung Cancer

5. Chinese Journal of Radiation Oncology: Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission

6. Chinese Journal of Radiation Oncology: Long-term Outcome of Radiotherapy for Nasopharyngeal Carcinoma

7. Chinese Journal of Radiation Oncology: Long-term Outcome of the Concurrent Use of Oral Panax Notoginseng and Radiotherapy in treatment for Nasopharyngeal Carcinoma of 60 randomized patients

8. Cancer: Radiotherapy for Stage III Non-Small-Cell Lung Cancer

9. Cancer: Impact on the Clinical Effect of Radiotherapy of the Involvement of the Carotid Sheath Area in Nasopharyngeal Carcinoma

10. Cancer: A Clinical Evaluation of the Concurrent Use of Radiotherapy and Chemotherapy in Treatment for Patients with Middle and Late Stage Nasopharyngeal Carcinoma

11. Cancer: Impact of Radiotherapy on the Clinical Effect of Chemotherapy in Treatment for Limited Stage and Extended Stage Small Cell Lung Cancer

12. Cancer: Impact of the Remaining Time of Cervical Lymph Node on the survival rate of patients after the Radiotherapy for Nasopharyngeal Carcinoma

13. Cancer: Relationship between the Cervical Lymph Node Biopsy and the Metastasis of Nasopharyngeal Carcinoma

14. Cancer: Evaluation of the Short-term Clinical Effect of Late Course Accelerated Hyperfractionated Radiotherapy in treatment for Non-Small-Cell Lung Cancer

15. Cancer: Evaluation of the Clinical Effect of Postoperative Radiotherapy for III a (N2) Stage Non-Small-Cell Lung Cancer

16. Cancer: Effectiveness of Radiotherapy for Patients with AIDS-related Primary Cerebral Lymphoma

17. Cancer: Long-term Efficacy of Radiotherapy on Children with Nasopharyngeal Carcinoma

18. Cancer: Long-term Prognostic Analysis of Patients with Malignant Pleural Mesothelioma

19. Cancer: Radiotherapy on Neck for Nasopharyngeal Carcinoma Patients with Negative Cervical Lymph Node

20. Cancer: Impact of Dose Boost in Skull Base on the Recurrence in stage T4 of Nasopharyngeal Carcinoma

21. Cancer: Impact of Amenorrhoea and Radiation Dose after Radiotherapy for Nasopharyngeal Carcinoma

22. Cancer: Radiotherapy for Recessive Nasopharyngeal Carcinoma

23. Cancer: Application of Magnetic Resonance Imaging to Clinical Classification of Nasopharyngeal Carcinoma

24. Cancer: Analysis of Prognostic Factors of Metastatic Nasopharyngeal Carcinoma

25. Cancer: Comparison between the Examination Staging and the Clinical Effect of CT or MRI before the Radiotherapy for Nasopharyngeal Carcinoma

26. Cancer: Cancer Incidence and Mortality in Guangzhou City from 2000 to 2002

27. Cancer: Incidence of colorectal cancer in Guangzhou City from 2000 to 2002

28. Cancer: Incidence of Children Tumor in Guangzhou City from 2000 to 2002

29. Chinese Journal of Clinical Oncology: Influence of Postoperative Radiotherapy on the Patients with Completely Resected Non-small Cell Lung Cancer

30. Tumor: Analysis of Prognostic Factors of Re-course Radiotherapy for Primary Recurrent Nasopharyngeal Carcinoma

31. Bulletin of Chinese Cancer: Comparison of Effectiveness for Nasopharyngeal Carcinoma Treated with Inducing Chemotherapy Plus Radiotherapy versus Concurrent Radio-chemotherapy

32. Bulletin of Chinese Cancer: An Analysis of Prognostic Factor for Locally Recurrent Nasopharygeal Carcinoma

33. Bulletin of Chinese Cancer: Impact of Computed Tomography and Magnetic Resonance Imaging on Staging for Nasopharyngeal Carcinoma

34. Bulletin of Chinese Cancer: An Analysis of Long-term Response with Radiotherapy in 49 Cases with Nasopharyngeal Carcinoma in Children

35. Bulletin of Chinese Cancer: An Analysis of Recurrent Site in 111 cases with Nasopharyngeal Carcinoma

36. Bulletin of Chinese Cancer: Cancer Registration in Guangdong Province

37. Bulletin of Chinese Cancer: A Contrastive Case-Control Study on the Risk Factors of Breast Cancer in Guangzhou City

38. Bulletin of Chinese Cancer: An Analysis of Incidence and Mortality of Nasopharyngeal Cancer in Guangzhou City

39. Bulletin of Chinese Cancer: Incidence and Mortality of Lung Cancer in Guangzhou City from 2000 to 2002

40. Bulletin of Chinese Cancer: The Role of Medical Records Scanning System in the Administration of Medical Records in Cancer Hospitals

41. Bulletin of Chinese Cancer: The Role of Tracing System in Computer-managed Medical Records

42. Bulletin of Chinese Cancer: The Role of Telephone in the Motivation Interview of Cancer Patients

43. Chinese Journal of Hospital Administration: Improve the quality and administration of Medical Records

Others

Having published 38 articles in Health News, Southern Weekly, Southern Metropolis Daily, Anti-Cancer News and other kinds of newspaper

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Mo Haoyuan was born in 1964 and graduated from the six-year program of the Department of Medicine, former Sun Yat-sen University of Medical Sciences in 1987. He is engaged in clinical work of nasopharynx carcinoma, nasopharynx carcinoma diagnosis and biopsy for difficult cases, and radiation therapy, chemotherapy and combination therapy for nasopharynx carcinoma. He is also engaged in teaching undergraduates and graduates, and scientific research. He has rich clinical experience. He has published many papers and undertaken many scientific research projects since he became a doctor.

1. Hao-Yuan Mo (lead author), Dong-Hua Luo, Hui-Zhi Qiu, Huai Liu, Qiu-Yan Chen, Lin-Quan Tang,Zong-Liang Zhong, Pei-Yu Huang, Zheng-Jun Zhao,Chang-Qing Zhang,Ying Zhang, Hai-Qiang Mai. Elevated Serum Endostatin Levels Associates with Poor Survival in Patients with Advanced-stage Nasopharyngeal Carcinoma. CLINICAL ONCOLOGY 2013Jan 2.

2. Sun Rui, Qiu Hui-Zhi, Mai Hai-Qiang , Zhang Qing, Hong ming-huang, Li Yan-Xian , Yang Jing, Sun Jian, Mo Hao-Yuan (corresponding author). Prognostic value and differences of the sixth and seventh editions of the UICC/AJCC staging systems in nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012 Oct 16.

3. Hao-Yuan Mo (lead author), Rui Sun,Jian Sun,Qing Zhang ,Wen-Jin Huang, Yan-Xian Li ,Jing Yang ,Hai-Qiang Mai. Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma. Radiat Oncol. 2012 Sep 7;7(1):149.

4. Jiang Li ,Hao-Yuan Mo (both as lead authors), Geng Xiong, Lin Zhang, Jia He, Zhou-Feng Huang, Zhi-Wei Liu, Qiu-Yan Chen, Zi-Ming Du, Li-Min Zheng, Chao-Nan Qian, and Yi-Xin Zeng. Tumor microenvironment MIF directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. The Journal of Biological Chemistry, 2012 Oct 12;287(42):35484-95.

5. PEI-YU HUANG,ZHE-YU SUN,CHUAN-MIAO XIE, QIU-YAN CHEN,YUE-FENG WEN, JUAN LI, HUI-ZHI QIU, HUAI LIU, ZONG-LIANG ZHONG,HAI-QIANG MAI & HAO-YUAN MO(corresponding author). Prognostic significance of the various classifications for parapharyngeal space involvement in nasopharyngeal carcinoma . Acta Oto-Laryngologica, 2012 Nov;132(11):1197-207.

6. Hai-Qiang Mai,Hao-Yuan Mo (both as lead authors),Jing-Feng Deng,Man-Quan Deng, Wei-Yuan Mai,Xiao-Ming Huang, Xiang Guo, Ming-Huang Hong. Endoscopic microwave coagulation therapy for early recurrentT1 nasopharyngeal carcinoma. EUROPEAN JOURNAL OF CANCER ,45(2009):1107-1110

7. Mo Haoyuan, Mai Haiqiang, Li Ningwei, Li Juan, Huang Wenjin, Guoxiang, Hong Minghuang. Study of secretory otitis media after radiotherapy in nasopharyngeal carcinoma and inquisition of prevention and treatment. Chinese Journal of Cancer Prevention and Treatment, 2007, 14 (13):1005-1007

8. Mo Haoyuan, Zhang Changqing, Feng Kaitao, Zhang Feng, Hong Minghuang, Sun Zheyu. Expression of P53 and PCNA in Nasopharyngeal Carcinoma and Their Relation with Clinical stage, VCA/IgA, EA/IgA, Radiation Sensibility,and Pognosis. Chinese Journal of Cancer, 2004, 23 (11S):1551-1554.

9. Mo Haoyuan, Zhang Feng, Hong Minghuang, Fan Wei, Zheng Lie, Min Huaqing. Positive Rate of Radionuclide Bone Imaging and Treatment in No Ostalgia Patients with New Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2002, 21 (3):323-325.

10. Mo Haoyuan, Deng Manquan, Mai Haiqiang, Qi Bin, Li Ningwei, Guo Xiang, Hong Minghuang. The influences and treatments of deafness in nasopharyngeal carcinoma patients after radiotherapy. Journal of Modern Oncology, 2009, 17 (10):1856-1858

11. Sun Zheyu, Mai Haiqiang, Xie Chuanmiao, Zhao Zhengjun, Qi Bin, Hong Minghuang, Guo Xiang, Mo Haoyuan (corresponding author). Prognostic influence of parapharyngeal space involvement in nasopharyngeal carcinoma. Chinese Journal of Cancer Prevention and Treatment, 2006, 13 (10):756-759

12. Zhao Zhengjun, Mo Haoyuan (advisor, second author), Zhang Changqing, Qi Bin, Li Juan, Hong Minghuang, Mai Haiqiang. Correlation of Pretreatment Serum Level of Endostatin to Posttreatment Distant Metastasis in Patients with Advanced Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2007, 26 (11):1243-1247.

13. Huang Wenjin, Mo Haoyuan (advisor, second author), Deng Manquan, Mai Haiqiang, Qi Bin, Li Juan, Hong Minghuang, Guo Xiang.  Relationship between cranial nerve involvement in nasopharyngeal carcinoma and the prognosis. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2009, 23 (21): 964-967.

14. Li juan, Mo Haoyuan (corresponding author), Mai Haiqiang, Mo Yunxian, Qiu Huizhi, Guo Xiang.  An investigation into the relationship between magnetic resonance nasopharyngeal carcinoma with parapharyngeal space invasion and prognosis. Journal of Chinese Oncology, 2011, 17 (1): 12-15.

15. Mai Haiqiang, Sun Zheyu, Xie Chuanmiao, Chen Qiuyan, Qiu Huizhi, Wen Yuefeng, Liu Huai, Zhong Zongliang, Guo Xiang, Mo Haoyuan (corresponding author).   Study on the effect of different degrees of parapharyngeal invasion on prognosis of nasopharyngeal carcinoma. Chinese Journal of Cancer Prevention and Treatment, 2011, 18 (17): 1333-1337.

16. Qiu Huizhi, Mo Haoyuan (corresponding author), Zhong Zongliang, Hua Yijun, Mai Haiqiang, Guo Xiang. Evaluation on the clinical application of China's 2008 staging and UICC 2002 and 2009 staging of nasopharyngeal cancer. Chinese Journal of Cancer Prevention and Treatment, 2011, 18 (18): 1470-1474.

17. Zhong Zongliang, Mo Haoyuan (corresponding author), Mai Haiqiang, Li Yanxian, Yang Jing, Cao Qiajia, Guo Xiang.  Clinical paired study of initial treatment of 86 cases of nasopharyngeal carcinoma with dermatomyositis. China Cancer. 2012, 21(3): 220-224.

18. Mo Haoyuan (lead author), Value of biopsy with nasopharyngeal fibroscopy in patients infected by EB virus without typically clinical symptom. Chinese Journal of Cancer, 2000

19. Mo Haoyuan (lead author), Clinical trial of five-color glossy ganoderma for relieving nasopharynx carcinoma patients radiotherapy reaction and improving immunity. Chinese Journal of Clinical Oncology, 1999

20. Mo Haoyuan (lead author), Difference and significance of nasopharyngoscope, CT, pathology biopsy in inspecting single side nasopharynx carcinoma T range -- with reports on 50 clinical cases. Chinese Journal of Cancer, 1998

Updated by International Office, Sun Yat-sen University Cancer Center

Sep/1995-Jul/2000  Bachelor in Medicine (equivalent to M.D. in the US)

Sun Yat-sen University of Medical Sciences,Guangzhou, P. R. China

Sep/2004-Sep/2006  Master of Medical Science in Oncology

Sun Yat-sen University ofMedical Sciences, Guangzhou, P. R. China

Sep/2006-Sep/2009 　Ph. D of Medical Science in Oncology

Sun Yat-sen University ofMedical Sciences, Guangzhou, P. R. China

25. Li J, Zeng XH, Mo HY, Rolén U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, LiMZ, Huang WL, Wang XN, Zeng YX, Masucci MG. Functional inactivation ofEBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumorimmunotherapy. PLoS One, 2007, 2(11):e1122.

Updated by International Office, Sun Yat-sen University Cancer Center

1.You R, Liu YP, Xie YL,...,Huang PY*, Chen MY*. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Mar 18;401(10380):917-927. (IF 168.9 )
2.Chen SY, Duan XT, Li HF, Peng L, Wang ZQ, Xu GQ, Hua YJ, Zou X, You R, Ouyang YF, Liu YP, Gu CM, Yang Q, Jiang R, Zhang MX, Lin M, Xie YL, Lin C, Ding X, Xie RQ, Duan CY, Zhang WJ, Huang PY*,  Chen MY*. Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.Cell Rep Med 2023 Nov 21;4(11):101279. (IF 14.3  )
3.You R, Liu YP, Huang PY (co-first author), et al. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial, JAMA Oncol. 2020 Sep 1;6(9):1345-1352.  (IF 28.4 )
4. Huang PY, Zeng Q, Cao KJ, Guo X, Guo L, Mo HY, Wu PH, Qian CN, Mai HQ, Hong MH. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.Eur J Cancer. 2015 Sep;51(13):1760-70. (IF  8.4  )
5. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, Wen BX, Wu YS, Mai HQ, Hong MH *. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial. Eur J Cancer. 2013 May;49(8):1923-31.  (IF 8.4 )
6. Peng PJ, Lv BJ, Wang ZH, Liao H, Liu YM, Lin Z, Con YY, Huang PY(Corresponding author). Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens.
Ther Adv Med Oncol. 2017 Feb;9（2）:68-74.  (IF 4.9)
7. Wu,X, Huang PY (Co-first author), Peng, PJ，Han F, Zhao C, Zhang L*. Long term follow up of a PhaseIII Study Comparing Radiotherapy with or without Weekly Oxaliplatin for Locoregionally Advanced Nasopharyngeal Carcinoma. Ann Oncol. 2013 Aug;24(8):2131-6. (IF  50.5  )
8. Xue C, Huang Y, Huang PY (Co-first author), Yu QT, Pan JJ, Liu LZ, Song XQ, Lin SJ, Wu JX, Zhang JW, Zhao HY, Xu F, Liu JL, Hu ZH, Zhao LP, Zhao YY, Wu X, Zhang J, Ma YX, Zhang L*.  Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2013 Apr;24(4):1055-61. (IF  50.5  )
9. Zhang L, MacIsaac KD, Zhou T, Huang PY(Co-first author), Xin C, Dobson JR, Yu K, Chiang DY, Fan Y, Pelletier M, Wang Y, Jaeger S, Krishnamurthy Radhakrishnan V, JeBailey L, Skewes-Cox P, Zhang J, Fang W, Huang Y, Zhao H, Zhao Y, Li E, Peng B, Huang A, Dranoff G, Hammerman PS, Engelman J, Bitter H, Zeng YX, Yao Y. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. Mol Cancer Res. 2017 Dec;15（12）:1722-1732. (IF 5.2)

Updated by International Office, Sun Yat-sen University Cancer Center

1989 Bachelor in Medicine
Radiological Medicine, Norman Bethune University of Medical Science　　
1997-2000 Ph. D of  Oncological Radiotherapy
Oncological radiotherapy, Université Paris XII Créteil Val de Marne 

（1）C. Lin, X.-S. Sun, S.-L. Liu, X.-Y. Li, N. Lu, X.-L. Li, L.-Q. Tang, L. Guo, Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases, Cancer Research and Treatment 52(3) (2020) 855-866. 
（2）S.-L. Liu, H.-X. Lin, C.-Y. Lin, X.-Q. Sun, L.-P. Ye, F. Qiu, W. Wen, X. Hua, X.-Q. Wu, J. Li, L.-B. Song, L. Guo, TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/beta-catenin signaling pathway and promoting the epithelial mesenchymal transition (vol 402, pg 117, 2021), Cancer Letters 524 (2022) 284-285. 
（3） H.-Z. Qiu, X. Zhang, S.-L. Liu, X.-S. Sun, Y.-W. Mo, H.-X. Lin, Z.-J. Lu, J. Guo, L.-Q. Tang, H.-Q. Mai, L.-T. Liu, L. Guo, M1 stage subdivisions based on F-18-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma, Therapeutic Advances in Medical Oncology 14 (2022). 
（4） Gu, L.-w., X. Zhang, J. Zhang, B.-b. Xiao, L.-p. Wu, L.-q. Tang, L. Guo & L.-t. Liu (2024) The prognostic value of pretreatment 18F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma. Oral Oncology, 156, 106928.
（5） Guo, J., Y. He, C. Lin, Q. Jiang, H.-W. Xing, Y.-C. Zhang, G.-Z. Shen, H.-X. Lin, L. Guo & Q. Yang (2023a) Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma. Oral Oncology, 146, 106574.
（6） Lin, C., N. Lu, J.-L. Liang, J. Guo, L.-W. Gu, R. Sun, L. Guo & Q. Yang (2023) Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma. Radiotherapy and Oncology, 186, 109802.
（7）Lu, Z.-J., T. Liu, J.-Y. Lin, S.-T. Pei, L. Guo, S.-L. Liu & H.-Q. Mai (2023) Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiotherapy and Oncology, 183, 109635.
（8）Zhu, Q., A. L. Zhong, H. Hu, J. J. Zhao, D. S. Weng, Y. Tang, Q. Z. Pan, Z. Q. Zhou, M. J. Song, J. Y. Yang, J. Y. He, Y. Liu, M. Li, W. M. Hu, C. P. Yang, T. Xiang, M. Y. Chen, G. Ma, L. Guo & J. C. Xia (2023) Acylglycerol kinase promotes tumor growth and metastasis via activating the PI3K/AKT/GSK3β signaling pathway in renal cell carcinoma. J Hematol Oncol 2020 Jan 3;13(1):2
（9）Jiang, T., H. Sun, T. Xu, S. Xue, W. Xia, X. Xiao, Y. Wang, L. Guo & H. Lin (2024) Significance of Pre-Treatment CALLY Score Combined with EBV-DNA Levels for Prognostication in Non-Metastatic Nasopharyngeal Cancer Patients: A Clinical Perspective. Journal of Inflammation Research, 17, 3353-3369.
（10）Chen, X. Y., Z. Q. Long, H. Y. Huang, W. Wen, F. Lin, L. Guo & H. X. Lin (2023) Predicting Survival of Patients with Nonmetastatic Breast Cancer Based on Fibrinogen-to-Albumin Ratio and Lymphocyte-to-Monocyte Ratio: A Nomogram-Based Assessment. Breast Care, 18, 374-389.

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Ming-Yuan Chen is currently a professor in the department of nasopharyngeal carcinoma (NPC) at Sun Yat-Sen University Cancer Center, Guangzhou, China. He specializes in NPC medical oncology and is a renowned oncology expert in China. Since 2015 he has been the deputy director of the department of NPC. In 2019, Dr. Chen organized and founded the Professional Committee of NPC of Guangdong Provincial Anticancer Association and was appointed the president. As a clinical scientist, Dr. Chen’s primary research interests focus on the comprehensive strategy and molecular mechanism of refractory NPC, especially recurrent, metastatic and necrotic NPC. 

Dr. Chen has devoted himself to establishing the minimally invasive surgery treatment system of NPC. He pioneered the use of minimally invasive surgery in recurrent and necrotizing NPC, which improved the overall survival of patients by 20%. Dr. Chen was the first person who applied minimally invasive surgery to early stage I NPC patients internationally, which revolutionized the treatment strategy for stage I NPC. In order to select proper patients for minimally invasive surgery, he established a new staging system for recurrent and necrotic NPC. A series of research achievements have been adopted by NPC clinical guidelines including the United Kingdom, the American College of Radiology and the China Anticancer Association, and he was awarded with the second prize in the Guangdong Medical Science and Technology Awards. Dr. Chen also became the first man in the Chinese Mainland that set up a course about minimally invasive surgery in American Otolaryngology-Head and Neck Surgery at the 120th Annual Meeting (AAO-HNSF). 

To deal with intractable metastasis in NPC, Dr Chen has also carried out several phase III multicenter randomized clinical trials and found that locoregional radiotherapy with chemotherapy improved overall survival by 21.9% in de novo metastatic NPC compared to chemotherapy alone, while neoadjuvant chemotherapy (NAC) followed by CCRT can reduce the risk of metastasis by 9.7% in local-regionally NPC patients compared to concurrent chemoradiotherapy (CCRT). Furthermore, he built a new molecular stage by combining the expression of p62 and N stage to identify patients that will be benefit from NAC followed by CCRT. A series of research achievements have meant the rewriting of the NPC National Comprehensive Cancer Network (NCCN) guidelines and he was awarded Clinical Cancer Advances 2021 by the American Society of Clinical Oncology (ASCO). Dr. Chen was invited to orally report these achievements at ASCO and the European Society for Medical Oncology (ESMO) in 2019. 

To uncover the molecular mechanism of recurrent and metastatic NPC, Dr. Chen has also performed genetic evolutionary analysis using multi-omics sequencing of paired primary tumors, recurrent tumors and metastasis samples, and portrayed the genetic evolutionary landscape of recurrent and metastatic NPC. Prof. David AB from Harvard University comments that this study provides a perfect example about how to track the evolutionary trajectory of NPC. Dr. Chen has published more than 40 peer-reviewed papers as corresponding or first author, including some papers in renowned journals such as JAMA Oncology, The Lancet Oncology, Cancer Research, Clinical Cancer Research, Journal of the National Cancer Institute, and Autophagy.

Dr. Chen has devoted himself to proposing the comprehensive effective treatment strategy through a series clinical trials for refractory nasopharyngeal carcinoma including recurrent, metastatic, and necrotic Nasopharyngeal Carcinoma, and unveiling the molecular mechanism of refractory nasopharyngeal carcinoma based on genetic and biological studies.

M.D. Clinical medicine, University of South China, China, 1993-1998

M.S. Otorhinolaryngology, Sun Yat-sen University, China, 1998-2001

Ph.D. Oncology, Sun Yat-sen University, China, 2004-2007

Selected publications
1. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Liu YP#, Wen YH#, Tang J#, Wei Y#, You R#, Zhu XL, Li J, Chen L, Ling L, Zhang N, Zou X, Hua YJ, Chen YM, Chen L, Lu LX, Chen MY*, Wen WP*. Lancet Oncol. 2021; 22(3):381-390. (IF: 33.752)

2. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. You R#, Liu YP#, Huang PY#, Zou X#, Sun R#, He YX, Wu YS,  Shen GP, Zhang HD, Duan CY, Tan SH , Cao JY, Li JB, Xie YL, Zhang YN, Wang ZQ,Yang Q, Lin M, Jiang R, Zhang MX, Hua YJ, Tang LQ, Zhuang AH, Chen QY, Guo L, Mo HY, Chen Y, Mai HQ, Ling L, Liu Q, Chua MLK*, Chen MY*.  JAMA Oncol. 2020; 6(9):1345-1352. (IF: 24.799)

3. Clonal Mutations Activate the NF-kappa B Pathway to Promote Recurrence of Nasopharyngeal Carcinoma. You R#, Liu YP#, Lin DC#, Li Q#, Yu T#, Zou X, Lin M, Zhang XL, He GP, Yang Q, Zhang YN, Xie YL, Jiang R, Wu CY, Zhang C, Cui C, Wang JQ, Wang Y, Zhuang AH, Guo GF, Hua YJ, Sun R, Yun JP, Zuo ZX, Liu ZX, Zhu XF, Kang TB, Qian CN, Mai HQ, Sun Y, Zeng MS, Feng L, Zeng YX, Chen MY*. Cancer Res. 2019; 79(23):5930-5943. (IF: 9.727)

4. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q#, Cao SM#, Guo L#, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X*, Hong MH*, Chen MY*. Eur J Cancer. 2019; 119:87-96. (IF: 7.275)

5. Genome-Wide Association Study of Susceptibility Loci for Radiation-Induced Brain Injury. Wang TM#, Shen GP#, Chen MY#, Zhang JB#, Sun Y#, He J, Xue WQ, Li XZ, Huang SY, Zheng XH, Zhang SD, Hu YZ, Qin HD, Bei JX, Ma J, Mu JB, Yao Shugart Y, Jia WH*. J Natl Cancer Inst. 2019; 111(6):620-628. (IF: 11.577)

6. A prognostic bio-model based on SQSTM1 and N stage identifies nasopharyngeal carcinoma patients at high risk of metastasis for additional induction chemotherapy. Yang Q#, Zhang MX#, Zou X#, Liu YP#, You R, Yu T, Jiang R, Zhang YN, Cao JY, Hong MH, Liu Q, Guo L, Kang T, Zhu X, Chen MY*. Clin Cancer Res. 2018; 24(3):648-658. (IF: 10.107)

7. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials Chen YP#, Tang LL#, Yang Q#, Poh SS#, Hui EP#, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM, Chen MY*, Ma J*. Clin Cancer Res. 2018; 24(8): 1824-1833. (IF: 10.107)

8. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Zou X#, You R#, Liu H#, He YX#, Xie GF#, Xie ZH, Li JB, Jiang R, Liu LZ, Li L, Zhang MX, Liu YP, Hua YJ, Guo L, Qian CN, Mai HQ, Chen DP, Luo Y, Shen LF, Hong MH, Chen MY*. Eur J Cancer. 2017; 77:117-126. (IF: 7.275)

9. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. You R#, Hua YJ#, Liu YP#, Yang Q#, Zhang YN, Li JB, Li CF, Zou X, Yu T, Cao JY, Zhang MX, Jiang R, Sun R, Mo HY, Guo L, Cao KJ, Lin AH, Sun Y, Qian CN, Ma J, Chen MY*. Theranostics. 2017; 7(8):2314-2324. (IF: 8.579)

10. The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis. You R#, Cao YS#, Huang PY#, Chen L#, Yang Q#, Liu YP, Zou X, Zhang YN, Jiang R, Zhang MX, Duan CY, Lin AH, Hong MH, Chen MY*. Theranostics. 2017; 7(19): 4825-4835. (IF: 8.579)

11. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC rTNM classification system. You R#, Zou X#, Wang SL#, Jiang R#, Tang LQ, Zhang WD, Li L, Zhang MX, Shen GP, Guo L, Qian CN, Mai HQ, Ma J, Hong MH, Chen MY*. Eur J Cancer. 2015; 51(13):1771-9. (IF: 7.275)

12. Elevated Beclin 1 expression is correlated with HIF-1 alpha in predicting poor prognosis of nasopharyngeal carcinoma. Wan XB#, Fan XJ#, Chen MY#, Xiang J, Huang PY, Guo L, Wu XY, Xu J, Long ZJ, Zhao Y, Zhou WH, Mai HQ, Liu Q, Hong MH*. Autophagy. 2010; 6(3):395-404. (IF: 9.77)

Updated April 2020 by International Office, Sun Yat-sen University Cancer Center

Dr. Chao-Nan Qian is the professor of Department of Nasopharyngeal Carcinoma, SYSUCC and president of Guangzhou Concord Cancer Center. Dr. Qian obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1992 and 1999, respectively. His post doctoral training at University of Texas MD Anderson Cancer Center and Van Andel Research Institute in Michigan provided him with great opportunities to explore the fields of tumorigenesis, tumor angiogenesis, tumor metastasis, and drug resistance of tumor cells. He was appointed as Research Scientist at Van Andel Research Institute in 2004 and Deputy Director of the Laboratory of Translational Cancer Research at National Cancer Center Singapore in May 2007. He then rejoined the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center (SYSUCC) as a Professor in June 2007, Assistant to The President of SYSUCC in January 2008, and Vice President of SYSUCC in November 2013. In 2019, Dr. Qian was appointed as President of Guangzhou Concord Cancer Center. Dr. Qian has published over 180 articles in reputable journals, and been supported by 1 state key grant and 4 general grants from the National Natural Science Foundation of China. He has been the associate/senior associate editor of Chinese Journal of Cancer / Cancer Communications since 2009.

M.D. 1992, Medicine
Sun Yat-sen University of Medical Sciences, Guangzhou, P.R. China

Residency Training 1992-1994, Medicine
The First Affiliated Hospital and The Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou, P.R. China

Ph.D. 1999, Oncology
Sun Yat-sen University of Medical Sciences, Guangzhou, P.R. China

Post-Doctoral Training  2000, Oncology
University of Texas MD Anderson Cancer Center,  Houston, Texas, USA

Post-Doctoral Training 2000-2003, Oncology
Van Andel Research Institute, Grand Rapids, Michigan, USA

(Selected publications from over 180 papers)
1. Xu L, Hu H, Zheng LS, Wang MY, Mei Y, Peng LX, Qiang YY, Li CZ, Meng DF, Wang MD, Liu ZJ, Li XJ, Huang BJ, Qian CN. ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner. Cancer Lett 2020; 482:74-89.

2. Yuan TZ, Zhan ZJ, Qian CN.  New frontiers in proton therapy: applications in cancers.  Cancer Commun (Lond) 2019; 39(1):61.

3. You R, Liu YP, Lin DC, Li Q, Yu T, Zou X, Lin M, Zhang XL, He GP, Yang Q, Zhang YN, Xie YL, Jiang R, Wu CY, Zhang C, Cui C, Wang JQ, Wang Y, Zhuang AH, Guo GF, Hua YJ, Sun R, Yun JP, Zuo ZX, Liu ZX, Zhu XF, Kang TB, Qian CN, Mai HQ, Sun Y, Zeng MS, Feng L, Zeng YX, Chen MY. Clonal Mutations Activate the NF-κB Pathway to Promote Recurrence of Nasopharyngeal Carcinoma.  Cancer Res 2019; 79(23):5930-5943.

4. Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY.  Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.  Eur J Cancer 2019; 119:87-96.

5. Liu YP, Li H, You R, Li JB, Liu XK, Yang AK, Guo X, Song M, Zhang Q, Guo ZM, Chen WK, Liu WW, Zou X, Hua YJ, Yang Q, Zhang YN, Sun R, Mo HY, Guo L, Lin AH, Mai HQ, Qian CN, Chen MY.  Surgery for isolated regional failure in nasopharyngeal carcinoma after radiation: Selective or comprehensive neck dissection.  Laryngoscope 2019; 129(2):387-395.

6. Li X, Qian X, Jiang H, Xia Y, Zheng Y, Li J, Huang BJ, Fang J, Qian CN, Jiang T, Zeng YX, Lu Z.  Nuclear PGK1 Alleviates ADP-Dependent Inhibition of CDC7 to Promote DNA Replication. Mol Cell 2018;72(4):650-660.e8.

7. Li X, Yu W, Qian X, Xia Y, Zheng Y, Lee JH, Li W, Lyu J, Rao G, Zhang X, Qian CN, Rozen SG, Jiang T, Lu Z. Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy. Mol Cell 2017; 66(5):684-697.

8. Zheng LS, Yang JP, Cao Y, Peng LX, Sun R, Xie P, Wang MY, Meng DF, Luo DH, Zou X, Chen MY, Mai HQ, Guo L, Guo X, Shao JY, Huang BJ, Zhang W, Qian CN. SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor. Cancer Res 2017; 77(2):579-589.

9. Li X, Qian X, Peng LX, Jiang Y, Hawke DH, Zheng Y, Xia Y, Lee JH, Cote G, Wang H, Wang L, Qian CN, Lu Z. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol 2016; 18(5):561-71.

10. Yang CF, Yang GD, Huang TJ, Li R, Chu QQ, Xu L, Wang MS, Cai MD, Zhong L, Wei HJ, Huang HB, Huang JL, Qian CN, Huang BJ. EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop. Oncogene 2016; 35(26):3419-31.

11. Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, Mai HQ, Zeng MS. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst 2015; 108(1).

12. Qian CN. Hijacking the vasculature in ccRCC-co-option, remodelling and angiogenesis. Nat Rev Urol 2013; 10(5):300-304.

13. Li J, Mo HY, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM, Zheng LM, Qian CN, Zeng YX. Tumor microenvironment MIF directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem 2012; 287(42): 35484-95.

14. Li XJ, Peng LX, Shao JY, Lu WH,Zhang JX, Chen S, Chen ZY, Xiang YQ, Bao YN, Zheng FJ, Zeng MS, Kang TB, ZengYX, Teh BT, Qian CN*. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis 2012; 33(7):1302-1309.

15. Chen QY, Wen YF, Guo L, Liu H,Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, HuaYJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: Phase III randomized trial. J Nat Cancer Inst 2011; 103(23):1761-1770.

16. Li GP, Wang H, Lai YK, Chen SC,Lin MC, Lu G, Zhang JF, He XG, Qian CN*, Kung HF*. Proteomic profiling between CNE-2 and its strongly metastaticsubclone S-18 and functional characterization of HSP27 in metastasis ofnasopharyngeal carcinoma. Proteomics 2011;11(14): 2911-20.

17. Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, Lee M, Liu ZW, Chen J, Zhang JX, Zhang HZ, He JH, Chen FL, Zhu XD, Huang MY, Liao DZ, Fu J, Shao Q, Cai MB, Du ZM, Yan LX, Hu CF, Ng HK, Wee JT, Qian CN, Liu Q, Ernberg I, Ye W, Adami HO, Chan AT, Zeng YX, Shao JY. Eight-signature classifier for prediction of nasopharnyngeal carcinoma survival. J Clin Oncol 2011; 29(34):4516-4525.

18. Li XJ, Ong CK, Cao Y, Xiang Y, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, Qin L, Bao YN, Zheng FJ,Chia CS, Iyer NG, Kang TB, Zeng YX, Soo KC, Trent JM, Teh BT, Qian CN. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 2011; 71(8): 3162-3172.

19. Qian CN, Furge K, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, VandenBeldt K, Resau JH, Anema J, Kahnoski RJ, Morreau H, Camparo P, Comperat E, Sibony M, Denoux Y, Molinie V, Vieillefond A, Eng C, Williams BO, Teh BT. Activation of thePI3K/AKT pathway induces transitional cell carcinoma of the renal pelvis: Identification in human tumors and confirmation in animal models. Cancer Res 2009;69(21): 8256-8264.

20. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, Tsarfaty I, Hudson E, Jackson DG, Petillo D, Chen J, Resau JH, Teh BT. Preparing the "soil": The primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006;66(21):10365-10376.

Updated May 2020 by International Office, Sun Yat-sen University Cancer Center

2004.9-2008.6：Sun Yat-sen University 

1998.9-2001.6：Harbin Medical University 

1993.9-1998.6：Harbin Medical University 

2007.4-2008.4：Van Andel Research Institute in Michigan of USA

9. Haoyuan Mo*, Rui Sun*, Jian Sun, Qing Zhang, Wenjin Huang, Yanxian Li, Jing Yang, Haiqiang Mai*. Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma. Radiation oncology, 7(1), pp 149, 2012.

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Luo Donghua is an attending physician. She graduated with the doctoral degree in Clinical Oncology from Sun Yat-sen University in 2010. At present, she serves as the attending physician in Sun Yat-sen University Cancer Center. Her research interests are in chemotherapy, radiation therapy, combination therapy for nasopharyngeal carcinoma; prevention and treatment of  radiotherapy side reaction; the mechanism of nasopharyngeal carcinoma distant metastasis and its prevention & treatment.

Chemotherapy, radiation therapy, combination therapy for nasopharyngeal carcinoma; prevention and treatment of  radiotherapy side reaction; the mechanism of nasopharyngeal carcinoma distant metastasis and its prevention & treatment.

09/1996-07/2001 Undergraduate studies under the Seven-year Program of Clinical Medicine, Zhongshan School of Medicine, SYSU

09/2001-07/2003 Postgraduate studies (master’s degree) under the Seven-year Program of Clinical Medicine, Zhongshan School of Medicine, SYSU

09/2007-07/2010 On-job doctoral degree’s program of Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

1. Bao YN, Cao X, Luo DH (Co-first author), Sun R, Peng LX, Wang L, Yan YP, Zheng LS, Xie P, Cao Y, Liang YY, Zheng FJ, Huang BJ, Xiang YQ, Lv X, Chen QY, Chen MY, Huang PY, Guo L, Mai HQ, Guo X, Zeng YX, Qian CN. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014;13(12):1958-69. (IF 5.25)

2. Luo DH, Chen QY, Liu H, Xu LH, Zhang HZ, Zhang L, Tang LQ, Mo HY, Huang PY, Guo X, Mai HQ. The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways. J Transl Med. 2013; 11(1):203. (IF 3.5)

3. Mo HY, Luo DH（Co-first author）, Qiu HZ, Liu H, Chen QY, Tang LQ, Zhong ZL, Huang PY, Zhao ZJ, Zhang CQ, Zhang Y, Mai HQ. Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2013;25(5):308-17. doi: 10.1016/j.clon.2012.11.009. (IF 2.1)

4. Liu H, Huang PY, Tang LQ, Chen QY, Zhang Y, Zhang L, Guo L, Luo DH, Mo HY, Xiang YQ, Qiu F, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Guo X, Cao KJ, Qian CN, Hong MH, Mai HQ. Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Med Oncol. 2013;30(4):685. doi: 0.1007/s12032-013-0685-6. Epub 2013 Aug 18.

5. Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, Luo DH, Huang PY, Zhang X, Lin XP, Mo YX, Liu LZ, Mo HY, Li J, Zou RH, Cao Y, Xiang YQ, Qiu F, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Mai HQ. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma epstein-barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31(23):2861-9. doi: 10.1200/JCO.2012.46.0816. Epub 2013 Jul 15.

6. Lin HX, Hua YJ, Chen QY, Luo DH, Sun R, Qiu F, Mo HY, Mai HQ, Guo X, Xian LJ, Hong MH, Guo L. Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2013; 32(9):502-11. doi: 10.5732/cjc.013.10004. Epub 2013 Jul 2.

7. Tang Y, Luo DH, Rong X, Shi X, Peng Y. Psychological disorders, cognitive dysfunction and quality of life in nasopharyngeal carcinoma patients with radiation-induced brain injury. PLoS ONE. 2012;7(6):e36529. (IF 4.1)

8. Chen MY, Wang SL, Zhu YL, Shen GP, Qiu F, Luo DH, Chen QY, Jiang R, Cao KJ, Qian CN, Hong MH. Use of a posterior pedicle nasal septum and floor mucoperiosteum flap to resurface the nasopharynx after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma. Head & Neck. 2012; 34(10):1383-8. (IF 2.4)

9. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs. radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011 Nov 4. (IF 14.69)

10. Tang Y, Li Y, Luo DH, Rong X, Ye J, Peng Y. Epilepsy related to radiotherapy in patients with nasopharyngeal carcinoma. Epilepsy Res. 2011;96(1-2):24-8. (IF 2.3)

11. Tang Y, Luo DH, Peng W, Huang F, Peng Y. Ocular ischemic syndrome secondary to carotid artery occlusion as a late complication of radiotherapy of nasopharyngeal carcinoma. J Neuroophthalmol. 2010;30(4):315-20.(IF 1.08)

12. Huang PY, Mai HQ, Luo DH, Qiu F, Li NW, Xiang YQ, Chen QY, Zhang L, Sun R, Cao KJ, Guo L, Deng MQ, Mo HY, Guo X, Zhang F, Cao SM, Chen MY, Guo Y, Fan YY, Hu W, Hua YJ, Xie GF, Hong MH. Controlled study on induction-concurrent chemoradiotherapy and induction chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chinese Journal of Cancer. 2009;28(10):1033-1042.

13. Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ, Hong MH. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012; 48(10):1038-44. (IF 2.857)

14. Luo DH, Cao JY, Ji H, Zhang H, Zeng MS, Hong MH. Preliminary analysis of the whole-genome-microarray-based results of peripheral blood in nasopharyngeal carcinoma patients. Chinese Journal of Cancer Prevention and Treatment. 2011;18(9):641-646.

15. Luo DH, Hong MH, Xiao XB. Analysis of the correlation between the saliva epidemal growth factor concentration and oral mucositis during nasopharyngeal carcinoma radiotherapy. Chinese Journal of Radiation Oncology. 2008;17(6):478-479.

16. Luo DH, Hong MH, Guo L, et al. Multivariable analysis of the oral mucositis during nasopharyngeal carcinoma radiotherapy and the clinical value of constructing the discriminative model. Chinese Journal of Cancer. 2005;24(7):850-854.

17. Luo DH, Guo L, Hong MH, Zhang F. Nasopharyngeal carcinoma with meningeal intracranial metastases: a case report. Chinese Journal of Oncology. 2005;27(1):62.

18. Luo DH, Hong MH. The mechanism, prevention and treatment of radioactive oral mucosal injuries. The Journal of Practical Medicine. 2003;19(2)205-207.

19. Cao KJ, Zhang AL, Ma WJ, Huang PY, Luo DH, Xia WX. Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study. Chinese Journal of Oncology. 2011;33(1)50-2

20. Ma WJ, Cao KJ, Xia WX, Luo DH. The relationship between re-staging and prognosis of recurrent nasopharyngeal carcinoma on the primary focus. China Cancer. 2010;Issue 11.

21. Huang PY, Hong MH, Zhang X, Mai HQ, Luo DH. The C-KIT expression and mutation in nasopharyngeal carcinoma cell lines and their reaction to Imatinib. Chinese Journal of Cancer. 2010;Issue 2.

22. Huang PY, Zhang L, Zhang X, Hong MH, Mai HQ, Luo DH. The mutation of C-KIT gene in patients with nasopharyngeal carcinoma. China Oncology. 2009;Issue 4.

23. Guo L, Lin HX, Qiu F, Luo DH, et al. Clinical experience in treating elderly patients with advanced nasopharyngeal carcinoma by using Capecitabine Tablets plus Paraplatin combined with concurrent chemoradiotherapy. Cancer Research on Prevention and Treatment. 2006;Issue 5.

24. Hua YJ, Hong MH, Luo DH, et al. Multivariable analysis of prognostic predictors for 406 patients with nasopharyngeal carcinoma. Chinese Journal of Clinical Oncology. 2005;32(8):435-438.

25. Hong MH, Mai HQ, Luo DH. Cost-effectiveness analysis of the adjuvant chemotherapy for N2-3 patients with nasopharyngeal carcinoma. China Cancer. 2000;9(12):548.

26. Shi XL, Ma SS, Luo DH, Rong XM, Li ZC, Fu RY, Shen QY, Tang YM. Clinical research on radiation-induced optic neuropathy in patients with nasopharyngeal carcinoma. Chinese Journal of Neuromedicine. 2013;12(1):76-79.

27. Li Y, Tang YM, Luo DH, Rong XM, Ye JH, Peng Y. Epilepsy related to radiotherapy in patients with nasopharyngeal carcinoma. Chinese Journal of Neuromedicine. 2012;11(10):986-988.

Updated by International Office, Sun Yat-sen University Cancer Center